INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,545,965 | +55.1% | 48,892 | +100.0% | 0.00% | +100.0% |
Q2 2023 | $996,908 | -10.2% | 24,446 | -17.9% | 0.00% | 0.0% |
Q1 2023 | $1,109,565 | -35.7% | 29,771 | -39.8% | 0.00% | -50.0% |
Q4 2022 | $1,725,276 | -31.1% | 49,449 | +9.2% | 0.00% | -33.3% |
Q3 2022 | $2,503,000 | +7.7% | 45,271 | +0.9% | 0.00% | 0.0% |
Q2 2022 | $2,323,000 | -37.7% | 44,877 | -12.5% | 0.00% | 0.0% |
Q1 2022 | $3,728,000 | -45.2% | 51,295 | -10.9% | 0.00% | -50.0% |
Q4 2021 | $6,805,000 | -7.5% | 57,549 | +5.0% | 0.01% | -25.0% |
Q3 2021 | $7,355,000 | -7.3% | 54,830 | -2.0% | 0.01% | 0.0% |
Q2 2021 | $7,934,000 | +92.1% | 55,930 | +8.6% | 0.01% | +60.0% |
Q1 2021 | $4,131,000 | +64.3% | 51,479 | +11.4% | 0.01% | +66.7% |
Q4 2020 | $2,515,000 | +225.8% | 46,229 | +19.0% | 0.00% | +200.0% |
Q3 2020 | $772,000 | +6.3% | 38,857 | +12.4% | 0.00% | 0.0% |
Q2 2020 | $726,000 | – | 34,557 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |